Tesamorelin AOD9604 CJC1295 Ipamorelin 12mg blend dosage explained: reconstitution math, typical research amounts, timing, and important safety limits.
A 12 mg tesamorelin AOD9604 CJC-1295 ipamorelin blend is dosed by total peptide weight, not by each peptide individually. Reconstituted with 3 mL of bacteriostatic water, the vial becomes 4 mg/mL, so 10 units on a U-100 insulin syringe delivers 400 mcg of the blend — roughly 100 mcg of each peptide if the four are split evenly. The ratio inside the vial is fixed, so you cannot adjust one peptide without shifting all four at the same time.
This guide covers the reconstitution math, what typical standalone research doses look like for each component, and why a four-peptide blend behaves very differently from four separate vials.
What Is Inside a 12 mg Four-Peptide Blend
The number on the label refers to combined peptide mass. Four compounds make up that 12 mg total, and each one works through a different pathway.
| Peptide | Primary mechanism | Typical standalone research dose | FDA status |
|---|---|---|---|
| Tesamorelin | GHRH analog; stimulates pituitary GH release | 1–2 mg subcutaneously once daily | FDA-approved as Egrifta SV for HIV-associated lipodystrophy |
| AOD9604 | Modified hGH fragment 176-191; studied for fat metabolism | 250–500 mcg once daily | Not FDA-approved for human use |
| CJC-1295 | GHRH analog; extends GH pulse duration | 100 mcg 1–3x daily (no DAC) or 1–2 mg weekly (with DAC) | Not FDA-approved for human use |
| Ipamorelin | Selective ghrelin receptor agonist; amplifies the GH pulse | 100–300 mcg, 2–3x daily | Not FDA-approved for human use |
Ratios vary by vendor. Some 12 mg vials are split 3 mg each; others use 5/3/2/2 or 4/4/2/2. Read the actual label before calculating anything, because a 3 mg vial and a 5 mg vial produce very different per-peptide exposure at the same draw volume.
How to Reconstitute and Calculate the Draw
- Draw 3 mL of bacteriostatic water into a syringe.
- Inject the water slowly down the inside wall of the vial instead of directly onto the powder.
- Swirl gently — do not shake — until the powder dissolves completely.
- Label the vial with the date and the resulting concentration.
With 3 mL of water in a 12 mg vial, the concentration is 4 mg/mL (4,000 mcg/mL). That makes the conversion simple: every 10 units on a U-100 syringe equals 400 mcg of total blend.
| Draw (U-100 units) | Total blend delivered | Each peptide in a 1:1:1:1 vial |
|---|---|---|
| 5 units | 200 mcg | 50 mcg |
| 10 units | 400 mcg | 100 mcg |
| 12.5 units | 500 mcg | 125 mcg |
| 25 units | 1,000 mcg (1 mg) | 250 mcg |
| 50 units | 2,000 mcg (2 mg) | 500 mcg |
If you use 2 mL of water instead, the concentration rises to 6 mg/mL and every draw delivers 1.5 times as much peptide. Water volume only changes the units you pull, not how much peptide sits in the vial.
Typical Research Dosages in Plain Numbers
Looking at each peptide on its own exposes the central problem with a fixed blend. The amounts studied separately are not proportional to one another.
- Tesamorelin: The FDA label for Egrifta SV uses 2 mg once daily, delivered subcutaneously.
- Ipamorelin: Most published work uses 100–300 mcg per dose, sometimes two or three times daily.
- CJC-1295: Without DAC, 100 mcg per dose is common; the DAC version is dosed at 1–2 mg per week.
- AOD9604: Research protocols generally land around 250–500 mcg once daily.
In a 1:1:1:1 vial, matching the 2 mg tesamorelin figure would mean injecting 8 mg of total blend and 2 mg of ipamorelin in the same syringe — roughly ten times the ipamorelin amount used in most studies. That is the tradeoff a blend forces on you.
Why Fixed-Ratio Blends Change the Math
A key mismatch is that tesamorelin and aod9604 act on different pathways and peak at different times. Tesamorelin drives a pituitary GH pulse through the GHRH receptor, while AOD9604 is studied for its effects on fat metabolism and does not trigger GH release at all. Mixing them in one syringe is convenient, but convenience is not the same as a matched pharmacokinetic profile.
The pair most often studied together is tesamorelin and ipamorelin, because one triggers GH release and the other amplifies the natural pulse. Even there, the dose ratio that makes sense for tesamorelin is far higher than the ratio that makes sense for ipamorelin.
Anyone building a tesamorelin ipamorelin dose chart runs into the same fixed-ratio wall. When people ask about cjc-1295 ipamorelin vs tesamorelin, the honest answer usually comes down to half-life and dosing frequency rather than raw strength. The same math applies to a fragment 176-191 & cjc-1295 & ipamorelin blend, which is a three-peptide version of the identical problem.
Timing, Injection Sites, and Practical Notes
- Timing: Most GH-related research protocols dose in the evening or before bed, when natural GH secretion is already elevated.
- Site rotation: Rotate between abdominal, thigh, and upper-arm subcutaneous sites to reduce irritation.
- Fasting window: GH secretagogues are often studied away from food, since insulin and glucose can blunt the GH response.
- Consistency: Because the ratio is fixed, changing your draw changes all four peptides at once. Track total blend units rather than individual peptides.
Storage, Safety, and Legal Status
Lyophilized powder should stay refrigerated or frozen and away from light. Once reconstituted, the vial is typically stored at 2–8 °C and used within a few weeks, though stability varies by peptide and by whether the water contains a preservative.
Tesamorelin is FDA-approved only as Egrifta SV for HIV-associated lipodystrophy. AOD9604, CJC-1295, and ipamorelin are not FDA-approved for human use, and a four-peptide blend is sold strictly as a research chemical.
Combining four peptides in a single vial also means combining four sets of unknowns. Interaction data, additive effects on blood sugar and cortisol, and long-term safety information simply do not exist for this combination. Anyone considering use in humans should consult a licensed healthcare professional rather than treating a research blend as a finished product.
Bottom line: a 12 mg vial reconstituted with 3 mL of water gives 4 mg/mL, and a typical draw lands between roughly 6 and 25 units on a U-100 syringe. The exact number depends on the label ratio, and no single figure works for every vial.
RELATED PEPTIDE TOPICTesa peptideFrequently Asked Questions
What is the dosage of a 12mg tesamorelin AOD9604 CJC-1295 ipamorelin blend?
Dosage is calculated as total blend weight, not per peptide. Reconstituted with 3 mL of bacteriostatic water, a 12 mg vial equals 4 mg/mL, so a 10-unit draw on a U-100 syringe delivers 400 mcg of blend and about 100 mcg of each peptide in a 1:1:1:1 vial. Most research protocols land between 250 mcg and 1 mg of total blend per injection. There is no universal number because the ratio differs by vendor.
How much bacteriostatic water should I add to a 12mg peptide blend?
Three milliliters is the most common choice because it produces a clean 4 mg/mL concentration where 10 units equals 400 mcg of total blend. Using 2 mL doubles the concentration to 6 mg/mL, while 6 mL halves it to 2 mg/mL. The water volume only changes how many units you draw, not how much peptide is in the vial.
Is a tesamorelin AOD9604 CJC-1295 ipamorelin blend FDA approved?
No. Only tesamorelin itself is FDA-approved, and only as Egrifta SV for HIV-associated lipodystrophy. AOD9604, CJC-1295, and ipamorelin are not FDA-approved for human use, and the four-peptide combination has no approved indication. Blends like this are sold as research chemicals and are not intended for human consumption.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.